1. Home
  2. GEO vs NAMS Comparison

GEO vs NAMS Comparison

Compare GEO & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geo Group Inc (The) REIT

GEO

Geo Group Inc (The) REIT

HOLD

Current Price

$30.24

Market Cap

3.9B

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$33.00

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GEO
NAMS
Founded
1984
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.1B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
GEO
NAMS
Price
$30.24
$33.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$39.67
$46.75
AVG Volume (30 Days)
2.0M
1.1M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
727.27
N/A
EPS
0.29
N/A
Revenue
$2,263,420,000.00
N/A
Revenue This Year
$13.74
$17.96
Revenue Next Year
$9.99
$540.65
P/E Ratio
$101.10
N/A
Revenue Growth
3.85
N/A
52 Week Low
$12.51
$17.97
52 Week High
$30.40
$42.21

Technical Indicators

Market Signals
Indicator
GEO
NAMS
Relative Strength Index (RSI) 79.71 55.23
Support Level $16.06 $30.34
Resistance Level N/A $37.27
Average True Range (ATR) 1.14 1.60
MACD 0.01 0.30
Stochastic Oscillator 91.62 92.58

Price Performance

Historical Comparison
GEO
NAMS

About GEO Geo Group Inc (The) REIT

The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services. The company operates in U.S, Australia and South Africa.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: